Symbols

ENTX

Entera Bio·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

Ample Liquidity

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ENTX

Entera Bio Ltd.

A clinical-stage biopharmaceutical company that developing orally delivered large molecule therapeutics

Industry

Pharmaceutical

Established Date

09/30/2009

Listing Date

06/28/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.enterabio.com

Security Type

Common stock

Office address

Kiryat Hadassah, Minrav Building - Fifth Floor, Jerusalem , Israel 9112002

Business

Introduction

Entera Bio Ltd., was incorporated on September 30, 2009 and commenced operations on June 1, 2010. The company is a clinical-stage company focused on developing first-in-class oral tablet forms of peptide or protein replacement therapies. The company focuses on underserved chronic conditions, and oral protein therapy has the potential to change the treatment model.

Company Financials

EPS

ENTX has released its 2025 Q3 earnings. EPS was reported at 0.07, versus the expected -0.09, beating expectations. The chart below visualizes how ENTX has performed over recent quarters, highlighting trends in earnings surprises.